A detailed history of Marshall Wace, LLP transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 350,641 shares of HRMY stock, worth $11.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
350,641
Previous 305,612 14.73%
Holding current value
$11.9 Million
Previous $9.22 Million 51.93%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.0 - $39.95 $1.35 Million - $1.8 Million
45,029 Added 14.73%
350,641 $14 Million
Q2 2024

Aug 14, 2024

BUY
$28.81 - $33.01 $5.22 Million - $5.98 Million
181,092 Added 145.43%
305,612 $9.22 Million
Q1 2024

May 15, 2024

BUY
$29.93 - $35.06 $3.73 Million - $4.37 Million
124,520 New
124,520 $4.18 Million
Q4 2022

Feb 14, 2023

BUY
$45.4 - $60.91 $6.43 Million - $8.62 Million
141,571 Added 663.56%
162,906 $8.98 Million
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $897,350 - $1.18 Million
21,335 New
21,335 $944,000
Q2 2022

Aug 15, 2022

SELL
$33.54 - $52.15 $2.82 Million - $4.38 Million
-83,961 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$33.14 - $51.13 $1.16 Million - $1.79 Million
34,974 Added 71.39%
83,961 $4.09 Million
Q4 2021

Feb 14, 2022

BUY
$34.09 - $43.91 $1.16 Million - $1.5 Million
34,098 Added 229.01%
48,987 $2.09 Million
Q3 2021

Nov 15, 2021

BUY
$25.68 - $38.61 $382,349 - $574,864
14,889 New
14,889 $570,000
Q2 2021

Aug 13, 2021

SELL
$25.96 - $33.44 $403,548 - $519,824
-15,545 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$27.56 - $40.37 $428,420 - $627,551
15,545 New
15,545 $514,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.